Enrolling by invitationPhase 2

Tirzepatide and Organ-specific Biological Aging

Tirzepatide and Organ-Specific Biological Aging: A Parallel-Design Feasibility Study Using Proteomic Organ Clocks in a Preventive Brain Health Cohort

Lead sponsor

Atria Research and Global Health Institute (ARGHI)

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

Estimated enrollment

Study population

Eligibility highlights

Primary endpoint

•Proteomic Brain Age Gap

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07906041

Org study ID26-02-569-2231

Timeline

Milestones

Study first posted2026-10-30actual

Last update posted2026-11-02actual

Study start2026-10estimated (month precision)

Primary completion2028-04estimated (month precision)

Study completion2028-09estimated (month precision)

Assets

Investigational agents

Tirzepatide

Who can enroll

Minimum age50 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Stable medical status (neurological, cardiovascular, and immuno inflammatory)

•Adults age 50-75 years

•Eligible and waitlisted for brain health program onboarding

•Willingness to undergo serial blood sampling, wearable monitoring, and MRI

•Willingness to be assigned to the interventional trial or non-interventional trial

•Willingness to accept tirzepatide treatment (interventional arm)

Exclusion criteria

•Major neurodegenerative disease (e.g., dementia)

•Clinical and correlative imaging history of ischemic or hemorrhagic stroke

•History of myocardial infarction (ACS) or heart failure

•Significant inflammatory, autoimmune, or infectious disease or current treatments/interventions likely to distort proteomic aging measures

•Contraindications to MRI

•Currently taking tirzepatide

•Pre-existing indications for tirzepatide (e.g., Type 2 diabetes, obesity, or obstructive sleep apnea)

•BMI less than 20.0

•Known contraindication to tirzepatide, including a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or known serious hypersensitivity to tirzepatide

•Active pancreatitis or history of recurrent pancreatitis

•Severe gastroparesis

•Clinically significant renal, hepatic, glycemic, or other laboratory abnormality that could increase the risk associated with tirzepatide treatment

•Current use of insulin or insulin secretagogues (e.g., sulfonylureas)

•Use of another incretin-based therapy unless discontinued for at least 35 days prior to enrollment

•History of clinically significant intolerance to tirzepatide or another incretin-based therapy

•Any other condition, illness, or medication that, in the judgment of the clinical investigative team, would make the individual an unsuitable candidate for tirzepatide or participation in this trial

•Contraindication to a wearable ring

•Pregnancy or lactation

•Prisoners

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Change in Proteomic Brain Age Gap From Baseline to Month 6

Time frame:From baseline to Month 6

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Between-Group Difference in Change in Proteomic Brain Age Gap From Baseline to Month 6

Time frame:From baseline to Month 6

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.